Joseph A Dougherty

US Patent:

RE38333, Nov 25, 2003

Filed:

May 29, 2002

Appl. No.:

10/159888

Inventors:

Murty N. Arimilli - Fremont CA
Kenneth C. Cundy - Belmont CA
Joseph P. Dougherty - New York NY
Choung U. Kim - San Carlos CA
Reza Oliyai - Foster City CA
Valentino J. Stella - Lawrence KS

Assignee:

Gilead Sciences, Inc. - Foster City CA

International Classification:

C07F 96512

US Classification:

544243, 544244, 546 23

Abstract:

Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure âOC(R ) OC(O)X(R) , wherein R independently is H, C -C alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR in which R is C -C alkyl; X is N or O; R is independently H, C -C alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro, âOâ, âN , âNR â, âN(R ) â or OR , R independently is âH or C -C alkyl, provided that at least one R is not H; and a is 1 or 2, with the proviso that when a is 2 and X is N, (a) two R groups can be taken together to form a carbocycle or oxygen-containing heterocycle, or (b) one R additionally can be OR. The compounds are useful as intermediates for the preparation of antiviral compounds or oligonucleotides, or are useful for administration directly to patients for antiviral therapy of prophylaxis. Embodiments are particularly useful when administered orally.

US Patent:

7198909, Apr 3, 2007

Filed:

Oct 29, 1999

Appl. No.:

09/830176

Inventors:

Yacov Ron - East Brunswick NJ, US
Joseph P. Dougherty - Hampton NJ, US

Assignee:

University of Medicine & Dentistry of New Jersey - New Brunswick NJ

International Classification:

C12P 21/06
C12P 21/00

US Classification:

435 691, 435 701

Abstract:

A long-lived, myeloid-committed stem cell population is disclosed. Also disclosed are methods and compositions for targeting this population with retrovirus vectors in gene therapy protocols for correcting congenital disorders of myeloid system and for potentiating immune responses to defined tumor and viral antigens.

US Patent:

20090163406, Jun 25, 2009

Filed:

Sep 30, 2005

Appl. No.:

11/576444

Inventors:

Harley I. Kornblum - Los Angeles CA, US
Daniel H. Geschwind - Santa Monica CA, US
Ichiro Nakano - Los Angeles CA, US
Joseph D. Dougherty - New York NY, US
Jorge Lazareff - Los Angeles CA, US
Paul S. Mischel - Los Angeles CA, US
Michael D. Masterman Smith - Playa Del Rey CA, US
Jing Huan - Los Angeles CA, US
Houman D. Hemmati - Baltimore MD, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

A61K 31/70
A61K 31/7088
A61K 38/02
A61K 38/16
A61K 31/20
C40B 40/08
G01N 33/53
A61P 35/00

US Classification:

514 12, 514 44, 514 2, 514 23, 514558, 506 17, 435 721

Abstract:

In one aspect, the invention provides composition and methods for the diagnosis, prognosis and treatment of tumors and cancers, e.g., brain cancers. In one aspect, the invention provides compositions and methods for inhibiting the growth, proliferation, differentiation and/or survival of a neural stem cell or a cancer cell, or progenitor stem cell thereof. In one aspect, the invention provides compositions and methods for identifying the genetic profile of a brain cancer cell or a self-renewing neural cancer stem cell. In one aspect, the invention provides methods employing these profiles to identify compounds that inhibit tumor growth.

US Patent:

59770899, Nov 2, 1999

Filed:

Nov 6, 1998

Appl. No.:

9/187763

Inventors:

Murty N. Arimilli - Fremont CA
Kenneth C. Cundy - Belmont CA
Joseph P. Dougherty - New York NY
Choung U. Kim - San Carlos CA
Reza Oliyai - Foster City CA
Valentino J. Stella - Lawrence KS

Assignee:

Gilead Sciences, Inc. - Foster City CA

International Classification:

A61K 31675
C07F 96561

US Classification:

514 81

Abstract:

Compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure --OC(R. sup. 2). sub. 2 OC(O)X(R). sub. a, wherein R. sup. 2 independently is H, C. sub. 1 -C. sub. 12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR. sup. 3 in which R. sup. 3 is C. sub. 1 -C. sub. 12 alkyl; X is N or O; R is independently H, C. sub. 1 -C. sub. 12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro, --O--, --N. dbd. , --NR. sup. 4 --, --N(R. sup. 4). sub. 2 -- or OR. sup. 3, R. sup.

US Patent:

59226951, Jul 13, 1999

Filed:

Jul 25, 1997

Appl. No.:

8/900746

Inventors:

Murty N. Arimilli - Fremont CA
Kenneth C. Cundy - Belmont CA
Joseph P. Dougherty - New York NY
Choung U. Kim - San Carlos CA
Reza Oliyai - Foster City CA
Valentino J. Stella - Lawrence KS

Assignee:

Gilead Sciences, Inc. - Foster City CA

International Classification:

A61K 31675
C07F 96512
C07F 96561

US Classification:

514 81

Abstract:

Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure --OC(R. sup. 2). sub. 2 OC(O)X(R). sub. a, wherein R. sup. 2 independently is H, C. sub. 1 -C. sub. 12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR. sup. 3 in which R. sup. 3 is C. sub. 1 -C12 alkyl; X is N or O; R is independently H, C. sub. 1 -C. sub. 12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro, --O--, --N. dbd. , --NR. sup. 4 --, --N(R. sup. 4). sub. 2 -- or OR. sup. 3, R. sup.

US Patent:

56889151, Nov 18, 1997

Filed:

Jun 1, 1995

Appl. No.:

8/457482

Inventors:

Yakov Ron - East Brunswick NJ
Joseph Dougherty - Hampton NJ

Assignee:

The University of Medicine and Dentistry of New Jersey - Newark NJ

International Classification:

C12N 500
C12N 508
C12Q 104

US Classification:

530380

Abstract:

Long term culture of resting T lymphocytes. The present invention provides methods and compositions for maintaining resting, mature T lymphocytes (cells) for long term in the absence of mitogens, antigens, or stimulatory cytokines, in which the T cells maintaining their ability to respond to nitrogens and allogenic cells. T cells cultured under such conditions can be used as target cells for retroviral vector-mediated gene transfer and implemented in certain gene therapy applications. The culturing conditions described herein allow for the continuous availability of T lymphocytes for various pharmacological, diagnostic, gene therapy, and experimental purposes, and can be utilized for any application requiring non-stimulated T lymphocytes. In specific examples, umbilical cord blood and peripheral blood T lymphocytes and endothelial-like adherent monocytes are cultured in DMEM, 2% 2-mercaptoethanol containing either 20% horse serum, or RPMI 2% 2-ME containing 10% fetal calf serum supplemented with basic fibroblast growth factor for up to three months.

US Patent:

60692499, May 30, 2000

Filed:

May 19, 1999

Appl. No.:

9/314607

Inventors:

Murty N. Arimilli - Fremont CA
Kenneth C. Cundy - Belmont CA
Joseph P. Dougherty - New York NY
Choung U. Kim - San Carlos CA
Reza Oliyai - Foster City CA
Valentino J. Stella - Lawrence KS

Assignee:

Gilead Sciences, Inc. - Foster City CA

International Classification:

C07F 96512
C07F 96561

US Classification:

544243

Abstract:

Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure --OC(R. sup. 2). sub. 2 OC(O)X(R). sub. a, wherein R. sup. 2 independently is H, C. sub. 1 -C. sub. 12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR. sup. 3 in which R. sup. 3 is C. sub. 1 -C. sub. 12 alkyl; X is N or O; R is independently H, C. sub. 1 -C. sub. 12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro, --O--, --N. dbd. , --NR. sup. 4 --, --N(R. sup. 4). sub. 2 -- or OR. sup. 3, R. sup.

US Patent:

60432306, Mar 28, 2000

Filed:

May 19, 1999

Appl. No.:

9/314606

Inventors:

Murty N. Arimilli - Fremont CA
Kenneth C. Cundy - Belmont CA
Joseph P. Dougherty - New York NY
Choung U. Kim - San Carlos CA
Reza Oliyai - San Ramon CA
Valentino J. Stella - Lawrence KS

Assignee:

Gilead Sciences, Inc. - Foster City CA

International Classification:

A61K 31675
C07F 96512

US Classification:

514 81

Abstract:

Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure -OC(R. sup. 2). sub. 2 OC(O) X(R). sub. a, wherein R. sup. 2 independently is H, C. sub. 1 -C. sub. 12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR. sup. 3 in which R. sup. 3 is C. sub. 1 -C12 alkyl; X is N or O; R is independently H, C. sub. 1 -C. sub. 12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, axido, nitro, --O--, --N. dbd. , --NR. sup. 4 --, --N(R. sup. 4). sub. 2 -- or OR. sup. 3, R. sup.